News
DMKPQ
0.030
0.00%
0.000
Weekly Report: what happened at DMKPQ last week (0520-0524)?
Weekly Report · 3d ago
Weekly Report: what happened at DMKPQ last week (0513-0517)?
Weekly Report · 05/20 09:56
Weekly Report: what happened at DMKPQ last week (0506-0510)?
Weekly Report · 05/13 10:00
Weekly Report: what happened at DMKPQ last week (0429-0503)?
Weekly Report · 05/06 10:03
Weekly Report: what happened at DMKPQ last week (0422-0426)?
Weekly Report · 04/29 10:06
Weekly Report: what happened at DMKPQ last week (0415-0419)?
Weekly Report · 04/22 10:02
Weekly Report: what happened at DMKPQ last week (0408-0412)?
Weekly Report · 04/15 09:57
Weekly Report: what happened at DMKPQ last week (0401-0405)?
Weekly Report · 04/08 10:00
Weekly Report: what happened at DMKPQ last week (0325-0329)?
Weekly Report · 04/01 09:59
Weekly Report: what happened at DMKPQ last week (0318-0322)?
Weekly Report · 03/25 10:01
Weekly Report: what happened at DMKPQ last week (0311-0315)?
Weekly Report · 03/18 09:59
Weekly Report: what happened at DMKPQ last week (0304-0308)?
Weekly Report · 03/11 09:58
Weekly Report: what happened at DMKPQ last week (0226-0301)?
Weekly Report · 03/04 10:00
Weekly Report: what happened at DMKPQ last week (0219-0223)?
Weekly Report · 02/26 10:05
Weekly Report: what happened at DMKPQ last week (0212-0216)?
Weekly Report · 02/19 10:06
Weekly Report: what happened at DMKPQ last week (0205-0209)?
Weekly Report · 02/12 10:01
*News On DMK Pharmaceuticals Corp. (DMK) Now Under DMKPQ
Dow Jones · 02/07 22:08
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 27.9% to $0.37 during Tuesday's after-market session. DMK Pharmaceuticals (NASdaq:DMK) stock moved upwards by 22.84%. The company's market cap stands at $5.6 million. Vicarious Surgical shares increased by 5.4%.
Benzinga · 02/06 21:31
DMK Pharmaceuticals Warns Investors Amid Bankruptcy
DMK Pharmaceuticals (DMK) has released an update. The company is in the midst of Chapter 11 bankruptcy proceedings. DMK stock is extremely risky and speculative during the company's bankruptcy proceedings, according to the company. Investors should exercise caution and not rely on DMK's forward-looking statements.
TipRanks · 02/06 09:33
DMK Pharmaceuticals Expects Nasdaq Delisting Amid Bankruptcy
DMK Pharmaceuticals anticipates a delisting notice from Nasdaq after failing to meet eligibility requirements. The company is facing Chapter 11 bankruptcy. The expected delisting will not alter the company's obligation to report to the SEC. DMK's stock is expected to be sold off.
TipRanks · 02/06 09:32
More
Webull provides a variety of real-time DMKPQ stock news. You can receive the latest news about DMK Pharmaceuticals Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DMKPQ
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.